Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Zydus Cadila

Serum Institute-Novavax Seal Win-Win Deal For COVID-19 Vaccine

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in a few regions. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India till deal ends and non-exclusive rights for developing countries till pandemic lasts, with Novavax getting half of net revenue.

Commercial Coronavirus COVID-19

Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite

High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.

Research & Development Coronavirus COVID-19

India’s Bulk Drugs Incentive Scheme Finds First Takers

As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products – they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.

Manufacturing Policy & Regulation

India’s Bulk Drugs Incentive Scheme Finds Takers In Mankind, Aarti

As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.

Policy & Regulation Manufacturing
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Cadila Healthcare
    • Zydus Pharmaceuticals USA
    • German Remedies
    • Zynesher Pharmaceuticals USA LLC
    • Nesher Pharmaceuticals Inc
    • Quimica e Farmaceutica Nikkho do Brasil Ltda
    • Bremer Pharma GmbH
    • Nippon Universal Pharmaceuticals
    • Zydus Discovery DMCC
    • Zydus Urosciences
    • Sentynl Therapeutics, Inc.
UsernamePublicRestriction

Register